Day: January 29, 2025

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) — Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to announce the signing of a $10.0 million seismic data licensing sales contract for 3D seismic data located in West Central Alberta. Pulse’s data library provides extensive seismic coverage critical for today’s data focused exploration and development companies throughout Western Canada. The Company is also pleased to provide a preliminary update on recent licensing revenue. Since October 1, 2024, the Company has licensed $21.7 million of data. Of this amount, $5.6 million was licensed in the fourth quarter of 2024, bringing expected total revenue for 2024 to $23.4 million. For 2025, including the deal announced today, total licensing revenue is $16.1 million. “As owners of Canada’s largest licensable...

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) — At the request of the Canadian Investment Regulatory Organization, Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company”) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity. About Global Uranium Corp. Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. The Company currently holds key uranium projects: the Wing Lake Property in the Mudjatik Domain of Northern Saskatchewan, Canada; the Northwest Athabasca Joint Venture with Forum Energy Metals Corp. and NexGen Energy Ltd. in the Northwest Athabasca region of Saskatchewan, Canada; and the Great Divide Basin District Projects, the Gas Hills District...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORM Paris, January 29, 2025, 7pm CET AB Science SA (Euronext – FR0010557264 – AB) today provides an update on its masitinib platform. The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ Highlights of the presentation are the following: Amyotrophic lateral sclerosisNew confirmatory study AB23005 simplified for enrolment and targeting best responders for masitinib will be initiated in line with recommendation of FDA and EMA Design validated by FDA and EMA Confirmatory study authorized by FDA Pathway to registration secured with agencies Discussion with partners facilitated First study AB10015 generated strong hypothesis on patients normal progressor and prior...

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris – France, January 29, 2025 – 6:00pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision immunology, announce a strategic collaboration to harness Scienta Lab’s advanced AI platform for modeling inflammatory diseases and identifying predictive biomarkers of efficacy for immunotherapies. Under this agreement, Scienta Lab will deploy EVA, its proprietary AI-powered multimodal foundation model dedicated to translational research in immunology, to discover multimodal signatures that can pinpoint predictive biomarkers for immunotherapy in immuno-inflammation. The aim is to identify patient subtypes...

January 29, 2025Announcement no. 02 BioPorto A/S appoints new interim Chairman of the Board COPENHAGEN, DENMARK, January 29, 2025, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that Board Member Henrik Juuel will be appointed interim Chairman of the Board of Directors in BioPorto A/S as John McDonough steps down and resigns as Chair and member of the Board of Directors at the end of this month. Henrik Juuel joined the Board of Directors of BioPorto A/S in 2024 and has more than 30 years of experience from the Life Science industry. Henrik is EVP & CFO of Bavarian Nordic A/S since 2018. Henrik Juuel commented; “On behalf of the full board, I want to express our deepest gratitude...

PRESS RELEASE | January 29th 2025, 5.45pm 2024 REVENUES Thanks to its strategy of diversification, SYNERGIE continues to grow amid an uncertain economic environment and in 2024 posted sales of €3.2 billion, up +2.4%  in € m Q4 2024 Q4 2023 % Variance FY 2024 FY 2023 % Variance  International 502 483 +3.9% 1,919 1,816 +5.7%  France 317 320 -0.9% 1,265 1,293 -2.1%  Total 819 803 +2.0% 3,184 3,109 +2.4%Despite a challenging market, SYNERGIE continued to grow over the year, setting a new sales record at €3,184 million, up +2.4% on the 2023 financial year (+0.9% on a like-for-like basis). This performance was achieved with  the contribution of all the geographical regions in which the Group operates. International sales (+5,7%), which account for 60.3% of the Group’s business, were driven by an organic growth of +3.0%...